132 related articles for article (PubMed ID: 38647387)
1. Monomethyl Auristatin E (MMAE), a Payload for Multiple Antibody Drug Conjugates (ADCs), Demonstrates Differential Red Blood Cell Partitioning Across Human and Animal Species.
Yip V; Saad OM; Leipold D; Li C; Kamath A; Shen BQ
Xenobiotica; 2024 Apr; ():1-13. PubMed ID: 38647387
[No Abstract] [Full Text] [Related]
2. Preclinical Characterization of the Distribution, Catabolism, and Elimination of a Polatuzumab Vedotin-Piiq (POLIVY
Yip V; Lee MV; Saad OM; Ma S; Khojasteh SC; Shen BQ
J Clin Med; 2021 Mar; 10(6):. PubMed ID: 33806916
[TBL] [Abstract][Full Text] [Related]
3. Evaluation and use of an anti-cynomolgus monkey CD79b surrogate antibody-drug conjugate to enable clinical development of polatuzumab vedotin.
Li D; Lee D; Dere RC; Zheng B; Yu SF; Fuh FK; Kozak KR; Chung S; Bumbaca Yadav D; Nazzal D; Danilenko D; Go MAT; Williams M; Polson AG; Poon KA; Prabhu S
Br J Pharmacol; 2019 Oct; 176(19):3805-3818. PubMed ID: 31270798
[TBL] [Abstract][Full Text] [Related]
4. An Anti-CD22-
Yu SF; Lee DW; Zheng B; Del Rosario G; Leipold D; Booler H; Zhong F; Carrasco-Triguero M; Hong K; Yan P; Rowntree RK; Schutten MM; Pillow T; Sadowsky JD; Dragovich PS; Polson AG
Mol Cancer Ther; 2021 Feb; 20(2):340-346. PubMed ID: 33273056
[TBL] [Abstract][Full Text] [Related]
5. A Novel Anti-CD22 Anthracycline-Based Antibody-Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs.
Yu SF; Zheng B; Go M; Lau J; Spencer S; Raab H; Soriano R; Jhunjhunwala S; Cohen R; Caruso M; Polakis P; Flygare J; Polson AG
Clin Cancer Res; 2015 Jul; 21(14):3298-306. PubMed ID: 25840969
[TBL] [Abstract][Full Text] [Related]
6. Microtubule and tubulin binding and regulation of microtubule dynamics by the antibody drug conjugate (ADC) payload, monomethyl auristatin E (MMAE): Mechanistic insights into MMAE ADC peripheral neuropathy.
Best RL; LaPointe NE; Azarenko O; Miller H; Genualdi C; Chih S; Shen BQ; Jordan MA; Wilson L; Feinstein SC; Stagg NJ
Toxicol Appl Pharmacol; 2021 Jun; 421():115534. PubMed ID: 33852878
[TBL] [Abstract][Full Text] [Related]
7. Development of a generalized pharmacokinetic model to characterize clinical pharmacokinetics of monomethyl auristatin E-based antibody-drug conjugates.
Chang HP; Cheung YK; Liu S; Shah DK
Br J Clin Pharmacol; 2024 Jul; 90(7):1637-1655. PubMed ID: 38566392
[TBL] [Abstract][Full Text] [Related]
8. Characterization of Site-Specifically Conjugated Monomethyl Auristatin E- and Duocarmycin-Based Anti-PSMA Antibody-Drug Conjugates for Treatment of PSMA-Expressing Tumors.
Lütje S; Gerrits D; Molkenboer-Kuenen JD; Herrmann K; Fracasso G; Colombatti M; Boerman OC; Heskamp S
J Nucl Med; 2018 Mar; 59(3):494-501. PubMed ID: 29146698
[TBL] [Abstract][Full Text] [Related]
9. Payload-Binding Fab Fragments Increase the Therapeutic Index of MMAE Antibody-Drug Conjugates.
Bordeau BM; Nguyen TD; Polli JR; Chen P; Balthasar JP
Mol Cancer Ther; 2023 Apr; 22(4):459-470. PubMed ID: 36723609
[TBL] [Abstract][Full Text] [Related]
10. Lysosomal P-gp-MDR1 Confers Drug Resistance of Brentuximab Vedotin and Its Cytotoxic Payload Monomethyl Auristatin E in Tumor Cells.
Liu-Kreyche P; Shen H; Marino AM; Iyer RA; Humphreys WG; Lai Y
Front Pharmacol; 2019; 10():749. PubMed ID: 31379564
[TBL] [Abstract][Full Text] [Related]
11. Whole-Body Pharmacokinetics and Physiologically Based Pharmacokinetic Model for Monomethyl Auristatin E (MMAE).
Chang HP; Cheung YK; Shah DK
J Clin Med; 2021 Mar; 10(6):. PubMed ID: 33807057
[TBL] [Abstract][Full Text] [Related]
12. SGN-B7H4V, an investigational vedotin ADC directed to the immune checkpoint ligand B7-H4, shows promising activity in preclinical models.
Gray E; Ulrich M; Epp A; Younan P; Sahetya D; Hensley K; Allred S; Huang LY; Hahn J; Gahnberg K; Treuting PM; Trueblood ES; Gosink JJ; Thurman R; Wo S; Spahr K; Haass EJ; Snead K; Miller D; Padilla M; Smith AJ; Frantz C; Schrum JP; Nazarenko N; Gardai SJ
J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37793853
[TBL] [Abstract][Full Text] [Related]
13. Physiologically based pharmacokinetic modeling as a tool to predict drug interactions for antibody-drug conjugates.
Chen Y; Samineni D; Mukadam S; Wong H; Shen BQ; Lu D; Girish S; Hop C; Jin JY; Li C
Clin Pharmacokinet; 2015 Jan; 54(1):81-93. PubMed ID: 25223698
[TBL] [Abstract][Full Text] [Related]
14. Semi-mechanistic Multiple-Analyte Pharmacokinetic Model for an Antibody-Drug-Conjugate in Cynomolgus Monkeys.
Lu D; Jin JY; Girish S; Agarwal P; Li D; Prabhu S; Dere RC; Saad OM; Nazzal D; Koppada N; Ramanujan S; Ng CM
Pharm Res; 2015 Jun; 32(6):1907-19. PubMed ID: 25467958
[TBL] [Abstract][Full Text] [Related]
15. Development of a Physiologically-Based Pharmacokinetic Model for Whole-Body Disposition of MMAE Containing Antibody-Drug Conjugate in Mice.
Chang HP; Li Z; Shah DK
Pharm Res; 2022 Jan; 39(1):1-24. PubMed ID: 35044590
[TBL] [Abstract][Full Text] [Related]
16. Development and Properties of Valine-Alanine based Antibody-Drug Conjugates with Monomethyl Auristatin E as the Potent Payload.
Wang Y; Fan S; Zhong W; Zhou X; Li S
Int J Mol Sci; 2017 Aug; 18(9):. PubMed ID: 28841157
[TBL] [Abstract][Full Text] [Related]
17. Determination of drug-to-antibody ratio of antibody-drug conjugate in biological samples using microflow-liquid chromatography/high-resolution mass spectrometry.
Inoue K; Mochizuki T; Kasamori N; Komori T
Bioanalysis; 2022 Dec; 14(24):1533-1545. PubMed ID: 36825963
[TBL] [Abstract][Full Text] [Related]
18. Population pharmacokinetic analysis for tisotumab vedotin in patients with locally advanced and/or metastatic solid tumors.
Gibiansky L; Passey C; Voellinger J; Gunawan R; Hanley WD; Gupta M; Winter H
CPT Pharmacometrics Syst Pharmacol; 2022 Oct; 11(10):1358-1370. PubMed ID: 35932175
[TBL] [Abstract][Full Text] [Related]
19. Antibody-Drug Conjugate Using Ionized Cys-Linker-MMAE as the Potent Payload Shows Optimal Therapeutic Safety.
Wang Y; Liu L; Fan S; Xiao D; Xie F; Li W; Zhong W; Zhou X
Cancers (Basel); 2020 Mar; 12(3):. PubMed ID: 32245171
[TBL] [Abstract][Full Text] [Related]
20. CYP Suppression in Human Hepatocytes by Monomethyl Auristatin E, the Payload in Brentuximab Vedotin (Adcetris
Wolenski FS; Xia CQ; Ma B; Han TH; Shyu WC; Balani SK
Eur J Drug Metab Pharmacokinet; 2018 Jun; 43(3):347-354. PubMed ID: 29264831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
